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Abstract
Neuroblastoma (NB) is one of the most common pediatric solid tumors originating from the neural crest lineage.
Despite intensive treatment protocols including megatherapy with hematopoietic stem cell transplantation, the
prognosis of NB patients remains poor. More effective therapeutics are required. High vascularity has been de-
scribed as a feature of aggressive, widely disseminated NB. Our previous work demonstrated the overexpression
of vascular endothelial growth factor (VEGF) in NB, and we showed that an anti–VEGF receptor (VEGFR-2) antibody
could induce sustained NB tumor suppression and regression. Sunitinib is a kinase inhibitor targeting platelet-
derived growth factor receptors and VEGFRs and, therefore, a promising antiangiogenic agent. In this study, we in-
vestigated the antitumor activity of sunitinib and its synergistic cytotoxicity with conventional (cyclophosphamide)
and novel (rapamycin) therapies. Both NB cell lines and tumor-initiating cells from patient tumor samples were used
in our in vitro and in vivo models for these drug testing. We show that sunitinib inhibits tumor cell proliferation
and phosphorylation of VEGFRs. It also inhibits tumor growth, angiogenesis, and metastasis in tumor xenograft
models. Low-dose sunitinib (20 mg/kg) demonstrates synergistic cytotoxicity with an mTOR inhibitor, rapamycin,
which is more effective than the traditional chemotherapeutic drug, cyclophosphamide. These preclinical studies
provide the evidence of antitumor activity of sunitinib both in the early stage of tumor formation and in the progres-
sive metastatic disease. These studies also provide the framework for clinical trial of sunitinib, alone and in com-
bination with conventional and novel therapies to increase efficacy and improve patient outcome in NB.
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Introduction
There has been considerable evidence in vivo, including clinical obser-
vations, that abnormal angiogenesis is correlated with active tumor
growth, metastatic potential, and poorer patient prognosis in a variety
of malignancies. Among the angiogenic growth factors, the vascular
endothelial growth factors (VEGFs) and their corresponding receptor
tyrosine kinases (RTKs; VEGFR-1 [fms-related tyrosine kinase 1 {Flt-1}
1], VEGFR-2 [Flk-1, kinase insert domain receptor {KDR}], and
VEGFR-3 [Flt-4]) play an indispensable role in modulating angio-
genesis and in the induction of vascular permeability and inflam-
mation [1–4]. Antiangiogenic therapies based on the inhibition of
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VEGF/VEGFR signalingwere reported to be powerful andwell-tolerated
therapy for solid tumors.
Neuroblastoma (NB) is the most common extracranial tumor of
childhood accounting for 7.2% cancers in children younger than
15 years [5]. Despite intensive multimodality clinical trials, including
the use of rescue autologous hematopoietic stem cell transplantation,
survival remains poor at less than 30% in patients with metastatic dis-
ease [6]. Vascular endothelial growth factor (particularly its isoform,
VEGF165) and its receptors VEGFR-1/2 have been found to be up-
regulated in various NB cell lines and in advanced high stage (III/IV)
NB [7,8]. Although VEGF primarily acts to promote angiogenesis,
it may also function as a paracrine angiogenic factor and acts as an
autocrine growth factor to promote NB cell growth directly [9]. In
addition, VEGF, through its effects on vascular permeability, results
in increased interstitial pressure, which inhibits the diffusion of chemo-
therapy agents into the tumor tissue.
Sunitinib (SU011248) is a novel small molecule multitarget inhibi-
tor of RTKs, an important family of growth factor receptors. It has
been shown in preclinical and clinical trials to have a direct antitumor
effect in addition to targeting RTKs, specifically the platelet-derived
growth factor receptor (PDGFR), VEGFR, KIT, Flt-3, and RET,
against many different malignancies including acute myeloid leukemia,
lung, colorectal, breast cancer, renal cell carcinoma, and thyroid carci-
noma [10–15].
Rapamycin (RAP) is a potent inhibitor of phosphatidylinositol
3-kinase (PI3K)/Akt pathway by targeting mTOR (mammalian target
of rapamycin). Possible additional mechanisms, through the reduction
of VEGF levels and vascular AKT inhibitor with consecutive inhibi-
tion of angiogenesis, have been described as well. Its anticancer effect
against different types of cancer has been demonstrated [27]. Conven-
tional chemotherapeutics protocols use a multimodality approach often
with high-dose chemotherapy, which is often associated with significant
toxicities and treatment break to allow for hematopoietic recovery.
Low-dose metronomic chemotherapy (LDM), the chronic administra-
tion of low doses of an antineoplastics agent, results in the inhibition
of tumor growth by direct cytotoxicity and also by an antiangiogenic
action targeting tumor vasculature [16]. The low therapeutic doses
equate to minimal treatment breaks thereby not allowing for tumor re-
growth and reducing drug resistance while minimizing acute/chronic
chemotoxicities. In this study, we evaluated both NB cell lines and
tumor-initiating cells (TICs) in in vitro studies and in vivo local and
metastatic xenograph murine models to investigate the role of sunitinib
in NB tumor growth, angiogenesis, and metastases. We hypothesized
that combining sunitinib with other antiangiogenic therapy would
suppress tumor growth andmetastasis more durably than a single agent.
Combination studies with rapamycin and LDM agents, cyclophospha-
mide, were expected to augment the individual antiangiogenic effect
of each agent alone.
Materials and Methods
Materials
Sunitinib (SU011248), (Z )-N -[2-(diethylamino)ethyl]-5-[(5-fluoro-
2-oxo-1,2-dihydro-3H -indol-3-ylidene)methyl]-2,4-dimethyl-1H -
pyrrole-3-carboxamide (S )-2-hydroxysuccinate (Mr 398.48), was
provided by Pfizer (Groton, CT). Antibodies were obtained from Santa
Cruz Biotechnology (Santa Cruz, CA) and Cell Signaling Technology
(Beverly, MA). The antiphosphotyrosine 4G10 antibody was obtained
from Millipore (Billerica, MA).
Cell Lines
SK-N-BE(2) and SH-SY5Y cells were obtained from ATCC
(Manassas, VA). LAN-5 cells were kindly provided by Dr. Robert
Seeger (Children’s Hospital Los Angeles), and NUB-7 cells were from
Dr. Herman Yeger (The Hospital for Sick Children, Toronto, Ontario,
Canada). Tumor-initiating cells (NB12, NB25, and NB88R2) were
kindly donated by Dr. Kaplan’s laboratory [16]. Neuroblastoma cell
lines were cultured in α-minimum essential medium with 10%
heat-inactivated fetal bovine serum at 37°C and harvested during ex-
ponential growth for use, storage, or further passage. Tumor-initiating
cells were maintained in Dulbecco’s modified Eagle’s medium: F-12
(3:1, Invitrogen, Carlsbad, CA) with 2%B-27 supplement (Invitrogen),
40 ng/ml basic fibroblast growth factor (Collaborative, Boston, MA),
20 ng/ml epidermal growth factor (Collaborative), and 100 U/ml
penicillin/streptomycin.
Nonobese Diabetic–Severe Combined Immunodeficiency Mice
Nonobese diabetic–severe combined immunodeficiency (NOD/
SCID) mice (Jackson Laboratory, ME) were used for local and meta-
static xenograft mouse models at 4 weeks of age. The mice were
housed in an isolated sterile containment facility and fed ad libitum
with water and food pellets. The Animal Care Committee at the
Hospital for Sick Children approved the study. During the study,
the mice were observed daily for possible adverse effects of medica-
tions, signs of ill health such as ruffled/thinning fur, abnormal beha-
viors, or local erosion from the tumor.
Cell Viability Assay
Cells were seeded into 24-well tissue culture plates at a density of
200,000 cells per well in culture medium and incubated for 24 hours
at 37°C before starting drug treatment. Cells were exposed to increas-
ing concentrations of sunitinib for 72 hours. The viability of prolif-
erating cells in the control and treated media were measured with
an Alamar Blue assay according to manufacturer’s protocol (Trek
Diagnostics Systems, Inc, Cleveland, OH). Briefly, Alamar Blue was
diluted 1:10 in the cell culture media, and the fluorescent color change
was monitored after 3 hours. Colorimetrical evaluation of cell prolif-
eration was performed using a SPECTRAmax Gemini spectrophotom-
eter with 540 nm as excitation wavelength and 590 nm as emission
wavelength, and values were expressed as relative fluorescence units.
Sphere Formation Assay
Cells were seeded in triplicate in 96-well non–tissue culture treated
plates at 3000 cells per well (2000 cells per well for NB12) in 50 μl of
culture medium. Compounds were diluted to the indicated concentra-
tions and immediately added to seeded cells in a volume of 50 μl,
bringing the final volume to 100 μl. Wells were retreated with com-
pound at the indicated concentrations 3 days after plating. Cultures
were fixed with 4% paraformaldehyle (Electron Microscopy Sciences,
Hatfield, PA) at day 7, and the number of spheres was determined
manually. The percentage of control sphere number was calculated
as follows: (mean sphere number for treated wells / mean sphere num-
ber of 0.05% DMSO-treated wells) × 100.
Xenograft Development
Two xenograft mouse models were used in this study. For the lo-
calized NB xenograft models, SK-N-BE(2) cells (106 cells/ml) or
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NB12 cells (30,000) were injected into the subcutaneous groin fat
pad of the NOD-SCID mice. Tumor size was measured weekly in
two dimensions, and treatment started when tumor volume reached
approximately 0.5 cm3. For metastatic SK-N-BE(2) xenograft models,
cells (106 cells/ml) were resuspended in 0.1 ml of sterile phosphate-
buffered saline (PBS) and injected intravenously through the lateral tail
vein of the NOD-SCID mice.
Drug Treatment
Sunitinib (Sutent; Pfizer) was prepared according to manufacturer’s
instructions and were stored as 100-μg/ml aliquots at −20°C. It was
administered by daily gavage at incrementally increasing doses of 20,
30, and 40 mg/kg in a dextrose-water vehicle. Rapamycin was admin-
istered daily by intraperitoneal injection at a dose of 3 mg/kg. Cyclo-
phosphamide was administered in the drinking water at a dosage of
20 mg/kg per day as previously described [17].
An initial dose-response study was performed using both SK-N-BE
(2) and NB12 cells in localized xenograft mouse models. When the tu-
mor volumes reached approximately 0.5 cm3, themice were randomized
into four groups: control group and three groups assigned to receive
escalating doses of sunitinib (20, 30, and 40 mg/kg). Sunitinib was ad-
ministered by daily gavage, and the dextrose-water vehicle was used
alone for the control group. Mice were killed after 14 days, and tumors
were harvested and weighted. Two independent experiments were per-
formed for each treatment with five to six animals per group. The opti-
mal dose at which a response was demonstrated was identified and used
in further experiments. A dose-response study was also performed using
SK-N-BE(2) metastatic xenograft mouse models. Sunitinib was admin-
istered 2 weeks after tumor inoculation at the same dose as described
for the localizedmodel.Mice were killed after 14 days of drug treatment.
Organs, including liver, lung, kidney, and femur, were harvested for
histological diagnosis to determine the presence of metastases. Cardiac
tissue was hematoxylin and eosin–stained and examined for evidence
of cardiomyopathy.
Immunohistochemistry
A wedge section of each tumor was snap frozen in liquid nitrogen
and analyzed for microvessel density by immunofluorescence using
the endothelial cell marker CD34. After blocking with 4% BSA for
1 hour, slides were incubated with the primary antibody for CD34
(Ab8158-100, 1:50 dilution; Abcam, Cambridge, MA) overnight at
4°C followed by secondary fluorescein isothiocyanate AffiniPure donkey
antirabbit immunoglobulin G (711-095-152, 1:200 dilution; Jackson
ImmunoResearch Laboratories, West Grove, PA) for 1 hour at −4°C.
Slides were analyzed formicrovessel density with fluorescentmicroscopy.
Paraffin-embedded tumors were analyzed for microvessel density
by immunostaining with the endothelial cell marker von Willebrand
factor. Briefly, sections of paraffin-embedded tumors were incubated
overnight with polyclonal rabbit antihuman von Willebrand factor
antibody (no. A0082; DakoCytomation, Glostrup, Denmark) at 4°C.
All slides were subsequently washed three times in PBS and incubated
with a 1:100 dilution of biotin-conjugated donkey antirabbit immuno-
globulin G (Jackson ImmunoResearch Laboratories) for 1 hour at
room temperature. Slides were incubated with VECTASTAIN Elite
ABCKit (Vector Laboratories, Burlingame, CA) for 30minutes at room
temperature and then with DAB until desired staining was achieved,
followed by counterstaining with hematoxylin. To quantify tumor an-
giogenesis, three high-power (×400) fields of the highest vascular density
were digitally captured. Tumor angiogenesis is quantified and shown as a
bar graph by the pixel values for positive vonWillebrand factor staining
using Image J software.
Enzyme-Linked Immunosorbent Assay
At time of sacrifice, blood was collected from SK-N-BE(2) metastatic
model and plasma was analyzed for VEGF, VEGFR-1, and VEGFR-
2 expression using quantikine ELISA kit from the R&D Systems
(Minneapolis, MN) according to the manufacturer’s instruction.
Vascular Endothelial Growth Factor Receptors
Phosphorylation Assay
SK-N-BE(2) cells were grown for 48 hours to approximately 80%
confluency before the experiment. Sunitinib was added in two dilutions
(20 and 50 ng/ml) and incubated with cells for 1 hour at 37°C in cul-
ture medium without fetal bovine serum, followed by stimulation with
VEGF165 50 ng/ml at 37°C for an additional 5 minutes. The cells were
then lysed in lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM sodium
chloride, 5 mM EDTA, 1 mM EGTA, 1% NP-40, 2 mM sodium
ortho-vanadate, 1 mM phenylmethylsulfonyl fluoride, 5 μg/ml apro-
tinin, and 8 μg/ml leupeptin). Nuclei were removed by centrifugation
for 10 minutes at 4°C. Protein concentrations of the lysates were deter-
mined using BSA as a standard. Immunoprecipitation was conducted
using anti–Flt-1 and anti–Flk-1 antibodies. Proteins were resolved with
SDS-PAGE and subjected to Western blot analysis. To detect phos-
phorylation, blots were probed with an antiphosphotyrosine mono-
clonal antibody, 4G10, and the same Western blot analysis was probed
with anti–Flt-1 and anti–Flk-1 antibodies. All signals were detected
using Super Signal West Pico Chemiluminescent Substrate (Pierce,
Rockford, IL).
RNA Extraction
SK-N-BE(2) cells were cultured in fresh medium with or without
10 ng/ml of sunitinib for 3 hours. Total RNA was isolated and puri-
fied using ArrayGrade Total RNA Isolation Kit (SABiosciences,
Frederick, MD) according to the manufacturer’s instruction.
Microarray Analysis
Biotin-labeled complementary RNA was synthesized from 5 μg of
total RNA using the TrueLabeling-AMP 2.0 Kit (SABiosciences) ac-
cording to the manufacturer’s instructions. The labeled complemen-
tary RNA samples were hybridized to the nylon membrane printed
with 113 specified genes related to tumor angiogenesis. Data were
analyzed using GEArray Expression Analysis Suite software. Changes
in gene expression of more than two-fold were defined as significant.
Statistical Analysis
The data are presented as mean ± SE of the indicated number of
independent experiments. Statistical analysis was performed by non-
parametric analysis of variance of multiple comparisons using Fisher’s
least significant difference. P < .05 was considered to be significant.
Results
Effect of Sunitinib on NB Cell Lines
To study the cytotoxic effects of sunitinib, the NB cell lines, SK-
N-BE(2), NUB-7, SH-SY5Y, and LAN-5, were exposed to increas-
ing concentrations of sunitinib for 48 hours. As shown in Figure 1A,
428 Sunitinib in Neuroblastoma Models Zhang et al. Neoplasia Vol. 11, No. 5, 2009
sunitinib significantly inhibited NB cell proliferation in a concentration-
dependent manner. Plotting the log of the sunitinib concentrations, we
determined that the IC50 of sunitinib is approximately between 10 and
20 ng/ml, which is within the clinically relevant human trough serum
concentration (50-100 ng/ml).
Effect of Sunitinib on TICs from Primary NB
We next assessed the activity of sunitinib on TICs isolated from
the bone marrow of unfavorable prognosis NB patients. These TICs
have been reported to have characteristics of cancer stem cells and
form metastatic NBs after orthotopic injection into immunodeficient
Figure 1. In vitro antitumor effect of sunitinib on NB cell line and TIC lines. (A) Dose-response plot of NB cell lines after sunitinib treat-
ment. Neuroblastoma cell lines, SK-N-BE(2), NUB-7, SH-SY5Y, and LAN-5, were exposed to increasing concentrations of sunitinib for
72 hours and assayed with the AlamarBlue Cell Viability Assay. (B) A dose-response curve was generated by testing sunitinib against
three TIC lines (NB12, NB25, and NB88R2) and normal skin-derived precursor cells (FS90). Sphere formation assay was used for in vitro
testing, and spheres are counted after 7 days of treatment.
Figure 2. Effect of oral sunitinib on growth of established humanNB inNOD/SCIDmice. In localizedNB xenograft model, 1× 106 SK-N-BE(2)
or 30,000 ofNB12cellswere injected subcutaneously into the inguinal area ofNOD-SCIDmice. All treatment startedwhen the tumor reached
0.5 cm in diameter. Two independent experiments were performed for each treatment with five to six animals per group. (A) Sunitinib was
administered by gavage daily at three different doses (20, 30, or 40 mg/kg). Mice were killed after 14 days of treatment, and tumors were
dissected andweighed. Drug activity was defined by tumor growth delay and optimal T/C (T/C – average treated tumormass/average control
tumor mass). (B, C) Antitumor activity of sunitinib, cyclophosphamide, rapamycin, and their combinations. Sunitinib was administered at
20 mg/kg, rapamycin (RAP) at 3 mg/kg daily intraperitoneally, and cyclophosphamide (CTX) orally through the drinking water at the approxi-
mate dosage of 20 mg/kg per day.
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mice with as few as 10 cells. [18]. As shown in Figure 1B, three TIC
lines from different patients (NB12,NB25, andNB88R2) responded to
sunitinib treatment. The IC50 of sunitinib is approximately 10
3 ng/ml.
We also assessed the effect of Sunitinib on nontransformed human pe-
diatric neural crestlike stem cells, line FS90 (skin-derived precursors)
[18]. The IC50 for cytotoxicity on FS90 was approximately 10 μg/ml.
Determination of Antitumor Effect of Sunitinib in
NOD/SCID Mice
It has been shown by Fiebig [19] that xenograft models from fresh
tumor explants can be predictive of clinical outcome. We therefore
tested the ability of Sunitinib to affect tumor growth of SK-N-BE(2)
cells and TICs (NB12) in a murine localized xenograft tumor model
and in a metastatic model.
Localized xenograft tumors were established by the subcutaneous
inoculation of tumor cells into NOD/SCID mice. Drug activity was
defined by tumor growth delay and optimal T/C (T/C – average
treated tumor mass/average control tumor mass). As shown in Fig-
ure 2A, treatment with 20 mg/kg of sunitinib showed significant
reduction (P < .05) in primary tumor growth (%T/C: 49% for
SK-N-BE(2) and 55% for NB12 tumor), whereas no significant dif-
ference was observed among doses 20, 30, and 40 mg/kg. Because
the 20-mg/kg dose seemed to have an effect that was similar to that
of either 30 or 40 mg/kg, 20 mg/kg was determined to be the opti-
mal dose to be used in the combination drug treatments.
We also compared the effect of sunitinib in combination treat-
ment with cyclophosphamide or rapamycin. Sunitinib was adminis-
tered at 20 mg/kg by gavage, in combination with rapamycin 3 mg/kg
daily intraperitoneally and cyclophosphamide orally through the drink-
ing water at the approximate dosage of 20 mg/kg per day. In the local-
ized tumor model, sunitinib, as a single agent, demonstrated superior
activity than cyclophosphamide did. Combined therapy was more ef-
fective in achieving an overall reduction in tumor volume when suni-
tinib was used in conjunction with rapamycin (P < .05; Figure 2B).
Figure 3. The effect of sunitinib in NB metastasis formation. In our metastatic model, 1 × 106 SK-N-BE(2) cells were injected intrave-
nously through the lateral tail vein. Sunitinib treatment started 2 weeks after intravenous inoculation. Mice were killed after 14 days
treatment for the evaluation of metastases by both optical image and histology. (A) Only mice in control group showed signs of distress
and developed extensive liver metastasis and ascites. In the sunitinib treatment groups, only few scattered metastatic nodules were
observed. Histology slides showed significant deduction of number and size of metastatic sites in liver, lung, adrenal gland, and bone
marrow after treatment with sunitinib. (B) A significant difference in liver weight between control and all treatment groups (P < .01).
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Although sunitinib and cyclophosphamide administered together sig-
nificantly reduced tumor volume, there is no significant change when
compared with sunitinib monotherapy (Figure 2C ).
Efficacy of Sunitinib on NB Tumor Metastasis
For the metastatic model, mice were injected intravaneously with
106 SK-N-BE(2) cells, and the cells were allowed to implant for
7 days. After 7 days, the animals were treated either with PBS or with
different doses of sunitinib (20, 30, 40 mg/kg) for 14 days (Materials
and Methods), at which point all animals were euthanized, and ne-
croscopy was performed. The peritoneal cavity of each animal was
photographed, histology was performed, and the occurrence of tu-
mors was noted in the following organs: liver, lung, kidney, adrenal
gland, and bone marrow. Only mice in the control group showed
signs of distress and developed extensive liver metastasis and ascites.
Gross examination and histology of different organs showed a dra-
matic decrease in the numbers and size of metastatic sites formed
in the treated animals compared with the control group (Figure 3A).
We also observed a significant difference in liver weight between con-
trol and all treatment groups (P < .01; Figure 3B). Thus, sunitinib
shows significant efficacy for treatment of NB metastasis.
Efficacy of Sunitinib on NB Tumor Angiogenesis
Tumor samples from the above xenograft models were analyzed
immunohistochemically using the endothelial markers von Willebrand
factor and CD34 to determine the extent of angiogenesis. As shown in
Figure 4A, with increasing dose of sunitinib from 20 to 40 mg/kg, a
lower density of microvessels appeared in the tumor tissues, indicating
a dose-dependent inhibition.
To quantitate the antiangiogenic effect of sunitinib, three hot spots
from each von Willebrand factor–stained tumor were digitally cap-
tured. The software, Image J, assigns pixel values for positive von
Willebrand factor staining (Figure 4B), and the average of all the
pixels in all the tumors found in each treatment group is shown as a
bar graph (Figure 4C). Sunitinib (40 mg/kg) inhibited tumor angio-
genesis by 36% (P = .007).
Sunitinib Inhibits VEGF-Triggered Phosphorylation
of VEGFRs
Because sunitinib is effective as an antiangiogenic agent, we per-
formed further studies to investigate whether this treatment could also
affect the in vitro and in vivo production of VEGF as well as modulate
the expression and phosphorylation of its receptors in plasma by ELISA
Figure 4. The effect of sunitinib on NB tumor angiogenesis. Tumor samples from the above xenograft model were analyzed for micro-
vessel density. (A) Microvessels were identified by the endothelial cell maker, CD34, with immunofluorescence staining, whereas tumor
tissue was identified by 4′, 6-diamidino-2-phenylindole staining. (B) Microvessels were also identified by immunohistochemical staining
for von Willebrand factor by immunohistochemistry. Positive immunohistochemical (brown) staining indicates the presence of endo-
thelial cells and microvessel structure in tumor tissues. (C) To quantitate the antiangiogenic effect of sunitinib, three fields with tumor
angiogenesis from each von Willebrand factor–stained tumor section were digitally captured. Tumor angiogenesis is quantified and
shown as a bar graph by the pixel values for positive von Willebrand factor staining using Image J software.
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at the end of treatment. No appreciable changes in VEGF and VEGFRs
plasma levels were observed after sunitinib treatment (Figure 5A).
We also investigated whether sunitinib could abrogate VEGF-induced
VEGFRs tyrosine phosphorylation in NB cells. As shown in Figure 5B,
sunitinib inhibited VEGF-induced VEGFR-2 (Flk-1) tyrosine phos-
phorylation at 20 ng/ml as well as VEGFR-1 (Flt-1) phosphorylation
at 50 ng/ml. Taken together, these data indicated that sunitinib blocks
VEGF-triggered pathways by inhibiting VEGFRs phosphorylation,
likely contributing to its antitumor effects in NB cells.
Regulation of Angiogenesis-Related Genes by Sunitinib
Although we know that sunitinib inhibits RTKs, specifically the
PDGFR, VEGFR, KIT, FLT-3, and RET, little is known about
Figure 5. Inhibition of VEGF-induced phosphorylation of VEGFRs by sunitinib. (A) The plasma concentrations of VEGF and VEGFRs
(VEGFR-1 and VEGFR-2) were determined by ELISA at the end of sunitinib treatment. (B) SK-N-BE(2) cells were incubated with 20 or
50 ng/ml of sunitinib for 1 hour and then stimulated with 50 ng/ml VEGF for 5 minutes at 37°C. Vascular endothelial growth factor
receptors were immunoprecipitated from cell lysates. Western blot analysis was performed on immunoprecipitates with an antiphos-
photyrosine antibody (upper panel) and polyclonal anti-VEGFR antibodies (lower panel).
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complex interactions between these factors and their cooperative effects
in promoting tumor angiogenesis and metastasis. To address the genetic
mechanisms by sunitinib, altering the expression of other genes related
to tumor metastasis, we performed cDNA microarray analyses. We
screened the NB cell line, SK-N-BE(2), with 113 genes that have
been reported to be involved in modulating tumor angiogenesis and
compared this gene profile to the same cell line after treatment with
sunitinib. Changes in gene expression of more than two-fold were
defined as significant. In 34 genes extracted from the microarray data,
as shown in Table 1, only 1 gene, angiogenin (ANG), showed mar-
ginal increase (2.04-fold) after sunitinib treatment, and other 8 genes
downregulated after treatment. Among these downregulated genes are
transcription factors (HIF1A), growth factors and receptors (EFNA2,
PDGFB, and VEGFC and EDG1, respectively), and other angiogenic
factors (AGGF1 and PTEN ).
Discussion
High vascularity has been described as a feature of aggressive,
widely disseminated NB. Expression of VEGF is nearly ubiquitous
in NB primary tumors and has been demonstrated in all NB cell
lines tested to date, and high-circulating VEGF and basic fibroblast
growth factor levels were correlated with high-risk NBs. Increased
primary tumor VEGF expression, particularly VEGF165, correlates sig-
nificantly with advanced (stages III and IV) disease [7,8]. In our previ-
ous publications, we demonstrated that VEGFR-2 and, to a lesser
degree, VEGFR-1 are expressed within NB cell lines as well as primary
NBs, and VEGF/Flt-1 pathway is critical in promoting NB growth
under hypoxic conditions [20]. Sunitinib is a kinase inhibitor targeting
multiple RTKs, including PDGFRs andVEGFRs. Preclinical and clinical
studies using sunitinib showed tumor regression and prolonged survival
in mammary adenocarcinoma, melanoma, and leukemia [21–24]. Here,
we investigated the effect of sunitinib in NB preclinical models and
compared with LDM therapy on NB tumor growth, angiogenesis,
and metastasis. Our data demonstrated that sunitinib provided signifi-
cant anticancer activity against NB, and this effect was greater than
LDM therapy alone.
Rapamycin is a potent inhibitor of PI3K/Akt pathway and it inhibits
the activity of a protein called mTOR, a serine-threonine kinase mem-
ber of the cellular PI3K pathway. The PI3K/Akt/mTOR pathway plays
a central role in cell survival and proliferation. It is also involved in the
production of proangiogenic factors (e.g., VEGF) and in endothelial
cell proliferation [25,26]. Inhibition of several steps of this pathway
has been shown to confer favorable antitumor activity in a variety of
cancer types [27]. In preclinical studies, inhibiting mTOR with
RAD001 diminished the expression of VEGF in tumor-derived cell
lines and inhibited angiogenesis in vivo [28]. In this study, rapamycin
proved to be effective when used in combination with sunitinib. There-
fore, combining sunitinib and rapamycin could potentially be a more
effective therapy in the NB clinic. Work in our laboratory is being done
to further elucidate the mechanism of rapamycin action and whether
there is an additive antiangiogeneic effect.
Table 1. Angiogenesis Genes Regulated by Sunitinib Treatment in Microarray Analysis.
Symbol Description Level Change After Treatment
ANG Angiogenin, ribonuclease, RNase A family, 5 204.62%
FGFR3 Fibroblast growth factor receptor 3 (achondroplasia, thanatophoric dwarfism) 199.17%
EFNA1 Ephrin-A1 190.55%
NRP1 Neuropilin 1 174.21%
NUDT6 Nudix (nucleoside diphosphate linked moiety X)-type motif 6 154.34%
EFNB2 Ephrin-B2 152.99%
ANGPT2 Angiopoietin 2 149.26%
LAMA5 Laminin, alpha 5 147.18%
ECGF1 Endothelial cell growth factor 1 (platelet-derived) 146.69%
NOTCH4 Notch homolog 4 (Drosophila) 132.08%
VEGFB Vascular endothelial growth factor B 121.87%
MDK Midkine (neurite growth-promoting factor 2) 121.45%
CXCL5 Chemokine (C-X-C motif ) ligand 5 121.43%
PTN Pleiotrophin (heparin binding growth factor 8, neurite growth-promoting factor 1) 119.37%
KDR Kinase insert domain receptor (a type III RTK) 119.16%
TIMP1 TIMP metallopeptidase inhibitor 1 116.96%
ENG Endoglin (Osler-Rendu-Weber syndrome 1) 107.43%
PGF Placental growth factor, VEGF–related protein 101.50%
TIMP3 TIMP metallopeptidase inhibitor 3 (Sorsby fundus dystrophy, pseudoinflammatory) 99.95%
CXCL9 Chemokine (C-X-C motif ) ligand 9 99.02%
AKT1 V-akt murine thymoma viral oncogene homolog 1 96.64%
SERPINF1 Serpin peptidase inhibitor, clade F (alpha-2 antiplasmin), member 1 91.24%
IL1B Interleukin 1, beta 72.30%
AS1R2 Artificial sequence 1 related 2 (80% identity) (48/60) 59.59%
EFNA3 Ephrin-A3 56.87%
MMP2 Matrix metallopeptidase 2 (gelatinase A, 72-kDa gelatinase, 72-kDa type IV collagenase) 55.20%
PTEN Phosphatase and tensin homolog (mutated in multiple advanced cancers 1) 49.77%
HIF1A Hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) 48.53%
AGGF1 Angiogenic factor with G patch and FHA domains 1 45.38%
VEGFC Vascular endothelial growth factor C 42.36%
EDG1 Endothelial differentiation, sphingolipid G-protein–coupled receptor, 1 41.46%
PDGFB Platelet-derived growth factor beta polypeptide (simian sarcoma viral (v-sis) oncogene homolog) 38.44%
EFNA2 Ephrin-A2 37.27%
TIMP3 Tissue inhibitors of metalloproteinase 3 (Sorsby fundus dystrophy, pseudoinflammatory) 32.80%
The intensity of shaded area represents the different expression levels of genes. The darkest shade (>200%) represents a significant increase, whereas the lightest shade (<50%) represents a significant
decrease of gene expression.
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According to the cancer stem cell hypothesis, cancer stem cells are
a minority of mutated stem cells or progenitors that have self-renewal
properties and also give rise to the heterogeneous mixture of cells that
make up the bulk of tumors [29]. Broad-spectrum chemotherapy may
eliminate the tumor mass, but cancer stem cells seem more resistant
than the rest of the tumor to cancer drugs and radiation [30]. Hence,
treatments targeting tumor stem cells would be required. In this study,
we isolated TICs from fresh samples of NB patients and used them in
our in vitro and in vivo models for drug testing. These TICs have been
shown to have tumor stem cell features in our published studies, and
they are capable of generating localized tumors by inoculating as few
as 50 spheres (approximately 3000 cells) [18]. Although the IC50 of
sunitinib for TICs is much higher than that for NB cell lines, our in vivo
results show that even at a lower dose (20mg/kg), sunitinib has a similar
antitumor effect between TICs and NB cell line. Combining the evi-
dence of VEGF/VEGFR pathway on angiogenesis, our data suggest
that the antitumor effect of sunitinib is more dependent on regulating
tumor microenvironment and angiogenesis.
The concept of an “angiogenic switch” in stimulatory and inhibitory
growth factors is important as angiogenesis is a key factor in the evolu-
tion of solid tumors, as in the presence of an inadequate blood supply
they cannot exceed a critical mass size of 1 to 2 mm and are maintained
in a steady state balance between cell proliferation and apoptosis [31].
The first antiangiogenesis drug approved by the Food and Drug Ad-
ministration to treat cancer was bevacizumab (Avastin) in 2004. It is
now used along with chemotherapy to treat some types of cancer
[32–34]. Since then, several other drugs with antiangiogenic properties
have been approved, including sorafenib [35] and sunitinib [36,37].
Despite current therapy-intensive multimodality protocols, the out-
come of patients with aggressive/unfavorable histological finding, NB
tumor remains poor. Using the NB cell line, SK-N-BE(2) and NB
TICs, NB12, we demonstrated the therapeutic potential of a novel
antiangiogenic agent, sunitinib, a multi-RTK inhibitor that proved to
be able to block phosphorylation of the VEGFRs.
In human dose-finding studies, an oral dose of 50 mg/dose has
been associated with tumor response in adult patients and a man-
ageable toxicity profile [38]. Recently, congestive cardiac failure, reduc-
tion of left ventricular ejection fraction and hypertension have been
described in adults treated with repeating cycles of sunitinib in phase
1/2 trials [39,40]. To lower the risk of drug adverse effects, we used a
lower dose (20 mg/kg) of sunitinib combined with rapamycin. Com-
pared with high-dose monotherapy (40 mg/kg), more significant anti-
tumor effects were observed in combined treatment with low-dose
sunitinib (20 mg/kg) and rapamycin. Also, histological studies of heart
tissues did not show any evidence of cardiotoxicity (data not shown).
Although we know that sunitinib inhibits RTKs, specifically the
PDGFR, VEGFR, KIT, Flt-3, and RET, little is known about the
complex interactions between these factors and their cooperative ef-
fects in promoting tumor angiogenesis and metastasis. Our additional
finding demonstrated that sunitinib not only regulates tumor angio-
genesis through inhibiting tyrosine kinase receptors but also interacts
with other tumor angiogenic factors, which may be an alternative mech-
anism of action of sunitinib. By blocking multiple angiogenic signaling
pathways and their interactive loops, a better therapeutic effect could
be achieved.
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